ACADIA Pharmaceuticals (ACAD) News Today $15.21 +0.30 (+2.04%) As of 03:42 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Price T Rowe Associates Inc. MD Cuts Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Price T Rowe Associates Inc. MD cut its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 5.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 621,010 shares of the biopharmaceutical company's stock after selling 38,954 shares duriMay 5 at 4:14 AM | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider Sells $19,374.20 in StockMay 3 at 5:29 AM | insidertrades.com50,269 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Bought by Aquatic Capital Management LLCAquatic Capital Management LLC bought a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 50,269 shares of the biopharmaceutical compaMay 3 at 5:10 AM | marketbeat.comWhat's Next: Twist Bioscience's Earnings PreviewMay 2 at 6:20 PM | benzinga.comACADIA Pharmaceuticals (ACAD) Expected to Announce Earnings on WednesdayACADIA Pharmaceuticals (NASDAQ:ACAD) will be releasing its Q1 2025 earnings after the market closes on Wednesday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-7-acadia-pharmaceuticals-inc-stock/)May 2 at 9:48 AM | marketbeat.comEmerald Mutual Fund Advisers Trust Cuts Stock Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Emerald Mutual Fund Advisers Trust lessened its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 12.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 500,391 sharesMay 1, 2025 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Lowered to $22.00 at UBS GroupUBS Group cut their price target on shares of ACADIA Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating for the company in a report on Monday.April 30, 2025 | marketbeat.comUBS Group Issues Pessimistic Forecast for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock PriceApril 30, 2025 | americanbankingnews.comWho was Ryan Reynolds’ father, James Chester Reynolds? Deadpool star wishes late dad could’ve met his and Blake Lively’s daughtersApril 29, 2025 | msn.comBirchview Capital LP Cuts Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Birchview Capital LP cut its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 15.5% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 338,400 shares of the biopharmaceutical company's stock afterApril 28, 2025 | marketbeat.comBarclays PLC Increases Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Barclays PLC lifted its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 7.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 298,445 shares of the biopharmaceutical company's stocApril 28, 2025 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by LPL Financial LLCLPL Financial LLC lowered its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 64.1% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,370 shares of the biopharmaceuticaApril 28, 2025 | marketbeat.comRyan Reynolds Thinks His Late Dad Would've ‘Benefited' From Meeting His GirlsApril 27, 2025 | msn.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Dark Forest Capital Management LPDark Forest Capital Management LP trimmed its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 39.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 45,319 shares of the biopharmaceApril 27, 2025 | marketbeat.comRyan Reynolds Reflects on Father's Battle with Parkinson's Disease and the Importance of Modern TreatmentsApril 26, 2025 | msn.com“That’s not easy” - A Decade After His Father’s Death, Ryan Reynolds Opens Up About His Struggles With Parkinson’s DiseaseApril 26, 2025 | msn.comRyan Reynolds Reacts to Blake Lively's Speech Where She Alluded to Justin Baldoni Legal Battle (Exclusive)April 26, 2025 | msn.comRyan Reynolds Shares the Sweet Family Tradition His Father Started That He's Continuing with His 4 Kids (Exclusive)April 26, 2025 | msn.comFirst Trust Advisors LP Acquires 574,251 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)First Trust Advisors LP grew its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 27.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 2,700,125 shares of the biopharmaceutical company's stock after purchasing an additioApril 26, 2025 | marketbeat.comInvesco Ltd. Trims Stock Position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Invesco Ltd. trimmed its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 8.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 512,320 shares of the biopharmaceutical company's stock afteApril 26, 2025 | marketbeat.comAlpine Global Management LLC Makes New Investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Alpine Global Management LLC acquired a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 55,566 shares of the biopharmaceutical company's stockApril 24, 2025 | marketbeat.comAcadia Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2025April 23, 2025 | businesswire.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Purchased by Canada Pension Plan Investment BoardCanada Pension Plan Investment Board boosted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 19.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 780,700 shares of the biopharmaceutApril 23, 2025 | marketbeat.comMarshall Wace LLP Cuts Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Marshall Wace LLP lessened its stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 16.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 993,593 shares of the biopharmaceutical company's stoApril 22, 2025 | marketbeat.comAcadia Pharmaceuticals price target lowered to $18 from $19 at BofAApril 20, 2025 | markets.businessinsider.comWalleye Capital LLC Buys 137,201 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Walleye Capital LLC increased its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 336.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 178,007 shares of the biopharmaceutApril 20, 2025 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Sold by Russell Investments Group Ltd.Russell Investments Group Ltd. lowered its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 25.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 197,800 shares of the biopharmaceutical company'sApril 19, 2025 | marketbeat.comQ1 Earnings Forecast for ACAD Issued By Leerink PartnrsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities researchers at Leerink Partnrs raised their Q1 2025 earnings per share estimates for ACADIA Pharmaceuticals in a note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now anticipates that the biopharmaApril 18, 2025 | marketbeat.comBank of America Securities Sticks to Their Hold Rating for ACADIA Pharmaceuticals (ACAD)April 18, 2025 | markets.businessinsider.comLeerink Partnrs Issues Optimistic Forecast for ACAD EarningsACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) - Equities research analysts at Leerink Partnrs raised their Q2 2025 earnings per share (EPS) estimates for ACADIA Pharmaceuticals in a research note issued to investors on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now expects tApril 17, 2025 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Acquired by Rockefeller Capital Management L.P.Rockefeller Capital Management L.P. boosted its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 2.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,163,455 shares of the biophaApril 17, 2025 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Shares Bought by Renaissance Technologies LLCRenaissance Technologies LLC raised its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 204.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,226,533 shares of the biopharmaceutical company'sApril 15, 2025 | marketbeat.comJPMorgan Chase & Co. Acquires 272,236 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)JPMorgan Chase & Co. grew its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 61.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 713,360 shares of the biopharmaceutical company's stock after pApril 15, 2025 | marketbeat.comCapital Fund Management S.A. Sells 123,399 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Capital Fund Management S.A. reduced its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 15.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 660,630 shares of the biopharmaceuticalApril 14, 2025 | marketbeat.comF M Investments LLC Purchases New Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)F M Investments LLC acquired a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 64,660 shares of the biopharmaceutical company's stock, valued at approximately $1,187,000April 14, 2025 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Receives Consensus Rating of "Moderate Buy" from BrokeragesShares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) have been given a consensus rating of "Moderate Buy" by the sixteen analysts that are currently covering the company, Marketbeat.com reports. Eight equities research analysts have rated the stock with a hold rating and eight haveApril 14, 2025 | marketbeat.comDeclining Stock and Solid Fundamentals: Is The Market Wrong About ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)?April 13, 2025 | finance.yahoo.com35,883 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Purchased by Aviva PLCAviva PLC bought a new position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 35,883 shares of the biopharmaceutical company's stock, valued at aApril 12, 2025 | marketbeat.comAcadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 11, 2025 | businesswire.comInsider Selling: ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider Sells 1,028 Shares of StockACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) insider James Kihara sold 1,028 shares of the company's stock in a transaction on Tuesday, April 8th. The stock was sold at an average price of $14.82, for a total transaction of $15,234.96. Following the sale, the insider now directly owns 22,257 shares in the company, valued at $329,848.74. This trade represents a 4.41 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.April 10, 2025 | marketbeat.comACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) EVP Sells $40,132.56 in StockACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) EVP Mark C. Schneyer sold 2,708 shares of the firm's stock in a transaction that occurred on Tuesday, April 8th. The shares were sold at an average price of $14.82, for a total transaction of $40,132.56. Following the completion of the transaction, the executive vice president now directly owns 59,456 shares of the company's stock, valued at $881,137.92. This represents a 4.36 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.April 10, 2025 | marketbeat.comACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 12-Month Low - Time to Sell?ACADIA Pharmaceuticals (NASDAQ:ACAD) Sets New 52-Week Low - Here's WhyApril 10, 2025 | marketbeat.comACADIA Pharmaceuticals' (ACAD) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reaffirmed a "buy" rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Tuesday.April 10, 2025 | marketbeat.comSei Investments Co. Raises Stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Sei Investments Co. lifted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 57.4% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 50,430 shares of the biopharmaceutical company'April 9, 2025 | marketbeat.comAmerican Century Companies Inc. Purchases 50,238 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)American Century Companies Inc. grew its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 55.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 141,265 shares of the biopharmaceutical coApril 9, 2025 | marketbeat.comAster Capital Management DIFC Ltd Makes New $745,000 Investment in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Aster Capital Management DIFC Ltd bought a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 40,609 shares of the biopharmaceutical company's stock, vApril 8, 2025 | marketbeat.comNorges Bank Buys Shares of 1,392,618 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Norges Bank purchased a new position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 1,392,618 shares of the biopharmaceutical company's stock, valued at appApril 8, 2025 | marketbeat.com36,161 Shares in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Bought by Raymond James Financial Inc.Raymond James Financial Inc. bought a new stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 36,161 shares of the biopharmaceutical company's stApril 8, 2025 | marketbeat.comSchroder Investment Management Group Sells 264,938 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)Schroder Investment Management Group reduced its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) by 49.7% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 268,034 shares of the biopharmaceutical compApril 7, 2025 | marketbeat.comKLP Kapitalforvaltning AS Invests $376,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)KLP Kapitalforvaltning AS acquired a new stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 20,500 shares of the biopharmaceutical company's stApril 7, 2025 | marketbeat.com Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Media Mentions By Week ACAD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACAD News Sentiment▼0.510.72▲Average Medical News Sentiment ACAD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACAD Articles This Week▼138▲ACAD Articles Average Week Get ACADIA Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Qiagen News Roivant Sciences News Revolution Medicines News Lantheus News BridgeBio Pharma News TG Therapeutics News Legend Biotech News Sarepta Therapeutics News Telix Pharmaceuticals Limited American Depositary Shares News ADMA Biologics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACAD) was last updated on 5/5/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredMusk's warning signal: Prepare before the cascade beginsWhen Elon Musk triggered his AI layoff plan, most analysts missed what it really meant. Louis Navellier didn’t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ACADIA Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ACAD Stock Free ACAD Stock Alerts